Daratumumab for the treatment of AL amyloidosis

References

• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924–1933.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91:947–956.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–1822.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128:159–168.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957–4959.
   PubMed Web of Science ®Google Scholar
• Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol. 2006;30:673–683.
   PubMed Web of Science ®Google Scholar
• Gertz MA. The classification and typing of amyloid deposits. Am J Clin Pathol. 2004;121:787–789.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–1207.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662–3670.
   PubMed Web of Science ®Google Scholar
• Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–769.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–1093.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741–3749.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48:557–561.
   PubMed Web of Science ®Google Scholar
• Cordes S, Dispenzieri A, Lacy MQ, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012;118:6105–6109.
   PubMed Web of Science ®Google Scholar
• Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143:369–373.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Rajkumar SV. Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol. 2017;14:73–74.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119:4860–4867.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–615.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lim SH, Kim SJ, et al. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid. 2014;21:261–266.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391–4394.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Oriol A, Lahuerta JJ, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015;170:804–813.
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9:51.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Sher T, Fenton B, Akhtar A, et al. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128:1987–1989.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–902.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sarosiek S, Sloan JM, et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood. 2017;130(1):507.
   Google Scholar
• Roussel M, Stoppa A-M, Perrot A, et al. A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2017;130(Suppl):508.
   Web of Science ®Google Scholar
• Kimmich C, Schönland SO, Müller-Tidow C, et al. Daratumumab monotherapy in forty-eight heavily pretreated patients with advanced systemic light-chain amyloidosis. The XVIth International Symposium on Amyloidosis; March 26–29, 2018; Kumamoto, Japan: International Society of Amyloidosis; 2018.
   Google Scholar
• Abeykoon JP, Zanwar S, Kumar S, et al. Daratumumab-based therapies in patients with AL amyloidosis. The XVIth International Symposium on Amyloidosis; March 26–29, 2018; Kumamoto, Japan: International Society of Amyloidosis; 2018.
   Google Scholar
• Hossein Taghizadeh MA, Thomas R, et al. Daratumumab – a safe first-line treatment of cardiac AL amyloidosis in heavily compromised patients. The XVIth International Symposium on Amyloidosis; March 26–29, 2018; Kumamoto, Japan: International Society of Amyloidosis; 2018.
   Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–ee46.
   PubMed Web of Science ®Google Scholar
• McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54:1095–1104.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Otten HG, El Haddad O, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54:1105–1109.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS, Bainbridge S, Pahwa R, et al. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. Clin Biochem. 2016;49:1202–1204.
   PubMed Web of Science ®Google Scholar
• Ladwig PM, Barnidge DR, Willrich MAV. Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory. Clin Vaccine Immunol. 2017;24:e00545-16.
   PubMed Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55:1555–1562.
   PubMed Web of Science ®Google Scholar
• Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964–2972.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Avet-Loiseau H. Minimal residual disease negativity is a new end point of myeloma therapy. J Clin Oncol. 2017;35:2863–2865.
   PubMed Web of Science ®Google Scholar
• Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–3068.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35.
   PubMed Web of Science ®Google Scholar
• Landgren O, Devlin S, Boulad M, et al. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51:1565–1568.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95–112.
   PubMed Web of Science ®Google Scholar